CRISPR Therapeutics AG - Common Shares (CRSP)
32.24
-0.42 (-1.29%)
NASDAQ · Last Trade: Apr 4th, 7:15 PM EDT
Via The Motley Fool · April 3, 2025
Via The Motley Fool · March 31, 2025
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
Via Investor's Business Daily · March 31, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Via MarketMinute · March 27, 2025

Via The Motley Fool · February 28, 2025
Via Benzinga · March 15, 2025

On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.<
Via Benzinga · March 11, 2025

Via The Motley Fool · February 28, 2025

Via The Motley Fool · February 24, 2025

Via Benzinga · February 18, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via Benzinga · February 16, 2025

Via The Motley Fool · February 14, 2025

Via Benzinga · February 14, 2025

Via Benzinga · February 14, 2025

Via Benzinga · February 14, 2025

Via The Motley Fool · February 12, 2025

Via Benzinga · February 12, 2025

The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.
Via Investor's Business Daily · February 11, 2025

Via The Motley Fool · February 10, 2025

Via The Motley Fool · February 2, 2025

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.
Via Benzinga · January 31, 2025